Payment overview · 2025
General Payments
$8,380.35
35 reported records · 10 companies
Healthcare provider profile · identity verified
Donna E Sweet, MD
Allopathic & Osteopathic Physicians|General Practice · WICHITA, KS · NPI 1982679478
Verified facts
What the public records show
CMS Open Payments records show Donna E Sweet, MD received $8,380.35 in general payments during 2025 across 35 reported records.
Merck Sharp & Dohme LLC accounted for 81.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Rexulti.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 260 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Descovy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vemlidy by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rexulti by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GARDASIL 9 as an associated drug or biological on 35573 records involving 25304 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Gardasil 9 by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ISENTRESS as an associated drug or biological on 37 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Isentress by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PIFELTRO as an associated drug or biological on 7921 records involving 2912 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Pifeltro by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $6,850.82 | 81.8% | 9 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $807.15 | 9.6% | 11 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $579.64 | 6.9% | 8 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $30.40 | 0.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.07 | 0.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.89 | 0.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.38 | 0.3% | 1 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.19 | 0.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.67 | 0.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.14 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $5,150.00 | 1 |
| Food and Beverage | $1,709.53 | 29 |
| Travel and Lodging | $1,520.82 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DELSTRIGO Normalized: delstrigo |
Drug | Merck Sharp & Dohme LLC | $1,550.82 | 7 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $151.27 | 4 | 2025 |
Source payment records
|
|||||
| RUKOBIA Normalized: rukobia |
Drug | ViiV Healthcare Company | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $122.55 | 1 | 2025 |
Source payment records
|
|||||
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $122.40 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $30.40 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.07 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.89 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $21.38 | 1 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.67 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.14 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $12.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 260 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
260 | 30 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | GARDASIL 9 open payments reported associated product |
CMS Open Payments — General Payments 35573 supporting records · 25304 recipient NPIs · example record 1237992212 |
Gardasil 9 · 2024 Exact normalized brand match · 1 Part D row |
23 | 18 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | ISENTRESS open payments reported associated product |
CMS Open Payments — General Payments 37 supporting records · 24 recipient NPIs · example record 1238003286 |
Isentress · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | PIFELTRO open payments reported associated product |
CMS Open Payments — General Payments 7921 supporting records · 2912 recipient NPIs · example record 1237992198 |
Pifeltro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 6992 | 5023 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 5498 | 5483 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 1765 | 1753 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 1372 | 1371 |
| Atorvastatin Calcium | Atorvastatin Calcium | 359 | 69 |
| Gabapentin | Gabapentin | 301 | 59 |
| Lisinopril | Lisinopril | 294 | 66 |
| Levothyroxine Sodium | Levothyroxine Sodium | 293 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 278 | 59 |
| Omeprazole | Omeprazole | 268 | 57 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 260 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 212 | 31 |
| Trazodone Hcl | Trazodone Hcl | 206 | 36 |
| Simvastatin | Simvastatin | 185 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 181 | 43 |
| Meloxicam | Meloxicam | 178 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 176 | 38 |
| Metformin Hcl | Metformin Hcl | 170 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 148 | 21 |
| Furosemide | Furosemide | 141 | 32 |
| Losartan Potassium | Losartan Potassium | 141 | 30 |
| Twinrix | Hepatitis A And B Vaccine/Pf | 128 | 85 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 126 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 122 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 120 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 117 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 117 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 109 | 18 |
| Eliquis | Apixaban | 101 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 100 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 99 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 95 | 22 |
| Mirtazapine | Mirtazapine | 94 | 16 |
| Ibuprofen | Ibuprofen | 90 | 23 |
| Dicyclomine Hcl | Dicyclomine Hcl | 89 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 85 | 27 |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 84 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 84 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | suppressed |
| Cephalexin | Cephalexin | 81 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 79 | suppressed |
| Ozempic | Semaglutide | 74 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 74 | 15 |
| Potassium Chloride | Potassium Chloride | 71 | 20 |
| Alendronate Sodium | Alendronate Sodium | 70 | 15 |
| Ondansetron Odt | Ondansetron | 69 | 15 |
| Prezcobix | Darunavir/Cobicistat | 69 | suppressed |
| Alprazolam | Alprazolam | 67 | 15 |
| Januvia | Sitagliptin Phosphate | 66 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 62 | 17 |
| Amoxicillin | Amoxicillin | 61 | 44 |
| Descovy | Emtricitabine/Tenofov Alafenam | 61 | suppressed |
| Estradiol | Estradiol | 59 | 15 |
| Ritonavir | Ritonavir | 56 | suppressed |
| Famotidine | Famotidine | 55 | 11 |
| Topiramate | Topiramate | 55 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 55 | 17 |
| Propranolol Hcl | Propranolol Hcl | 53 | 12 |
| Myrbetriq | Mirabegron | 52 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 24 |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 51 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 50 | suppressed |
| Efavirenz-Emtric-Tenofov Disop | Efavirenz/Emtricit/Tenofovr Df | 48 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 48 | 17 |
| Buspirone Hcl | Buspirone Hcl | 47 | suppressed |
| Darunavir | Darunavir | 47 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | suppressed |
| Atenolol | Atenolol | 46 | suppressed |
| Prednisone | Prednisone | 45 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | suppressed |
| Carvedilol | Carvedilol | 42 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | suppressed |
| Diazepam | Diazepam | 41 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 11 |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 39 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 38 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 36 | suppressed |
| Spironolactone | Spironolactone | 36 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 35 | suppressed |
| Tivicay | Dolutegravir Sodium | 35 | suppressed |
| Atazanavir Sulfate | Atazanavir Sulfate | 34 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 34 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 34 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 33 | suppressed |
| Acyclovir | Acyclovir | 33 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 33 | suppressed |
| Allopurinol | Allopurinol | 32 | suppressed |
| Celecoxib | Celecoxib | 32 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Isentress | Raltegravir Potassium | 31 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Levemir Flexpen | Insulin Detemir | 29 | suppressed |
| Methadone Hcl | Methadone Hcl | 29 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 29 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Fentanyl | Fentanyl | 25 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 12 |
| Azithromycin | Azithromycin | 24 | 18 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 24 | suppressed |
| Isentress Hd | Raltegravir Potassium | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Stribild | Elviteg/Cob/Emtri/Tenofo Disop | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Gardasil 9 | Hpv Vaccine 9-Valent/Pf | 23 | 18 |
| Livalo | Pitavastatin Calcium | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Pifeltro | Doravirine | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 22 | suppressed |
| Havrix | Hepatitis A Virus Vaccine/Pf | 21 | 18 |
| Bumetanide | Bumetanide | 20 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 15 |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Rexulti | Brexpiprazole | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | 13 |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 13 |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Scopolamine | Scopolamine | 15 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Dalfampridine Er | Dalfampridine | 14 | suppressed |
| Dronabinol | Dronabinol | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Nexium | Esomeprazole Magnesium | 14 | suppressed |
| Progesterone | Progesterone, Micronized | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Complera | Emtricita/Rilpivirine/Tenof Df | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 13 | suppressed |
| Abacavir-Lamivudine | Abacavir Sulfate/Lamivudine | 12 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 12 | suppressed |
| Efavirenz | Efavirenz | 12 | suppressed |
| Evotaz | Atazanavir Sulfate/Cobicistat | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Flunisolide | Flunisolide | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Prezista | Darunavir | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 12 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 12 | suppressed |
| Typhim Vi | Typhoid Vi Polysacch Vaccine | 12 | 12 |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Avonex Pen (4 Pack) | Interferon Beta-1a | 11 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Tretinoin | Tretinoin | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $8,380.35 · 35 records | Merck Sharp & Dohme LLC | APRETUDE, Auvelity, Biktarvy, CABENUVA, CAPLYTA, DELSTRIGO, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, Kerendia, REXULTI, RUKOBIA, Tlando, Yeztugo | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Gilead Sciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error